#United States #New Jersey #Everolimus #Breckenridge #Zortress

Breckenridge Pharmaceutical Unveils New Generic Immunosuppressant

Breckenridge Pharmaceutical, Inc., based in New Jersey and the U.S. subsidiary of Towa International, recently announced an exciting development for both patients and healthcare providers. The company is proud to introduce Everolimus Tablets, 1mg, a generic version of Novartis' popular immunosuppressant, Zortress®. This new offering aims to improve accessibility to essential medication for kidney and liver transplant patients.

Strategic Partnership with Natco Pharma

The launch of Everolimus Tablets was made possible through a collaborative effort with Natco Pharma Limited, a well-respected pharmaceutical manufacturer in India. This partnership underscores Breckenridge's commitment to expanding its portfolio of generic medications while ensuring high-quality production standards. The Everolimus Tablets will begin shipping to pharmacies, retail outlets, and clinics starting October 30, 2025.

Importance of Everolimus in Transplant Medicine

Everolimus, classified as an mTOR inhibitor, plays a critical role in preventing organ rejection among adult recipients of kidney and liver transplants. By suppressing the immune response, it helps ensure better outcomes for patients post-transplant. Breckenridge's generic version not only provides therapeutic efficacy but also addresses the increasing need for more affordable medication options in the growing field of organ transplantation.

Varied Strengths Available

With the introduction of the 1mg strength, Breckenridge now offers Everolimus Tablets in various dosages, previously making available the 0.25mg, 0.5mg, and 0.75mg strengths. This ensures that patients and their healthcare providers can tailor their treatment regimens to meet specific medical needs, which is critical in maintaining adherence to prescribed therapies.

Brian Guy, the President and Chief Commercial Officer of Breckenridge Pharmaceutical, emphasized the significance of affordability in healthcare, stating, "We are excited to now provide all strengths of Everolimus Tablets in both bottle and blister card formats. Our mission is to continue developing therapies that enhance access to effective treatments for patients while addressing their unmet medical needs."

Availability and Distribution

The Everolimus Tablets will be available at multiple outlets, including retail drugstores, mail order pharmacies, and healthcare clinics nationwide. This strategic distribution approach is intended to ensure that patients receive prompt access to their medications, facilitating smoother treatment journeys.

For medical professionals, it is crucial to understand the full scope of Everolimus Tablets, including recommended dosages, potential side effects, and interactions with other medications. Comprehensive information is provided on the Breckenridge website, ensuring healthcare providers can make informed decisions for their patients.

Commitment to Patient Health

Breckenridge Pharmaceutical, Inc. is dedicated to improving the health and well-being of patients, reflecting the company's ethos of quality service and on-time delivery. By partnering with manufacturers globally, Breckenridge strives to deliver effective and economical generic pharmaceuticals, positioning itself as a reliable entity in the healthcare sector.

As healthcare systems worldwide continue to evolve, the need for affordable access to important medications like Everolimus remains a pressing issue. Breckenridge's introduction of this generic form of Zortress® is a significant step in the right direction, encouraging better health outcomes and improved quality of life for countless patients dealing with organ transplants.

For further details and prescribing information, customers are encouraged to visit Breckenridge Pharmaceutical’s official website.

Overall, the launch of Everolimus Tablets signifies a notable milestone in Breckenridge's ongoing mission to enhance patient access to critical medications, reinforcing its role in shaping a healthier future for patients throughout the United States.